BSX— AI Stock Forecast & Price Targets
Published 6/14/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live BSX price forecast →
Boston Scientific has been cut in half from ~$109 to $46.91 amid WATCHMAN/EP guidance cuts, yet the underlying business still posted Q1'26 revenue of $5.20B with 69.4% gross margins and $1.34B net income — a stark disconnect between fundamentals and tape. With forward P/E of 12.6x, RSI at 29, analyst target of $76.57, and the Penumbra/Thunderbolt catalyst closing, this looks like an oversold quality compounder where the market has likely overshot, though knife-catching risk is real until price stabilizes above $50.
Wait for confirmation, don't catch the knife. RSI 29 and proximity to $46 52-week low set up a tradeable bounce, but trend is broken. Tactical entry: starter position (25% of intended size) at $46-47, add on a confirmed daily close above $52 with volume. Stop-loss below $44 (below recent low). Targets: $52 first, then $58 gap fill. Invalidation: daily close below $44, or another negative WATCHMAN datapoint.
Constructive. Forward P/E of 12.6x for a 17% sales grower with 69% gross margins is anomalously cheap for medtech. Catalysts: (1) Q2'26 earnings (next print) where guidance reset is critical, (2) Penumbra deal close and Thunderbolt launch, (3) potential WATCHMAN stabilization commentary. Expected return range over 3-6 months: +25% to +50% if guidance stabilizes ($58-70 zone). What would change my mind: a second guidance cut, further WATCHMAN share loss to competitors, or operating cash flow weakness extending beyond Q1'26.
BSX has a structural compounder profile — 16.5% 3-yr sales CAGR, 63% 3-yr EPS CAGR, expanding TAM in cardiology/neuromodulation/endoscopy. The Penumbra acquisition meaningfully expands neurovascular exposure. Multi-year drivers: stroke intervention TAM, structural heart, deep brain stimulation, drug-coated balloons. At analyst PT of $76.57 (+63%) the stock would re-rate toward 20x forward — consistent with peer medtech. Biggest structural risk: WATCHMAN was a key growth pillar; if competitive dynamics or reimbursement headwinds prove durable, the 'quality compounder' multiple won't return.
The fundamentals remain genuinely strong despite the stock collapse. TTM revenue is $20.61B with Sales Y/Y TTM of +17.4% and Q1'26 revenue of $5.20B (+11.6% Q/Q growth). Gross margins are excellent at 69.4% (Q1'26) and operating margins 20.6%, with Q1'26 net income of $1.34B (25.8% net margin, though boosted by what looks like a one-time item given prior quarters ran $672M-$797M). EBITDA TTM of $5.50B, FCF of $2.81B, and operating cash flow of $4.34B demonstrate genuine cash generation. Balance sheet is workable but not pristine: $11.03B total debt vs $1.45B cash, debt/equity of 0.43 (LT) — manageable given the EBITDA base (debt/EBITDA ~2x). ROE of 14.8% and ROIC of 9.7% are decent but not exceptional. The Q1'26 operating cash flow of just $348M vs $1.36B in Q4'25 is a yellow flag worth monitoring — could be working capital, could be deal-related. The 53% drawdown stems from guidance cuts on WATCHMAN and EP per the Truist note (PT cut from $85 to $64) and SeekingAlpha's 'broken compounder' framing — but the underlying P&L hasn't deteriorated to match the price reaction.
Tape is decisively broken across all timeframes. Weekly chart shows a textbook distribution top from the $100-108 zone in 2025 followed by a violent breakdown to $46.91 — Perf YTD -50.8%, Perf Half-Year -49.4%, Perf Year -52.4%. Daily chart shows price right at the 52-week low ($45.99) with SMA200 distance at -43%, SMA50 at -16.6%, SMA20 at -8.3%, indicating cascading lower highs and lower lows. RSI at 29.1 confirms deeply oversold. The 1h chart shows the recent capitulation low around $46 on June 12 followed by a small bounce — Kronos forecast band on the 1h points to a $60+ mean-revert which would be a +28% bounce. The 4h forecast similarly clusters around $85-92 over 1-3 months, and the 1d forecast targets $80 area. However, model directional accuracy is only 23.8% on this name (worse than coin flip), and MAPE rises to 85% at horizon 14 — so treat AI levels as aspirational, not predictive. Key support: $46 (current low). Key resistance: $52 (gap zone), $58 (pre-collapse base), then the open gap toward $80+.
The signal: Truist cut PT from $85 to $64 but kept Buy, explicitly citing WATCHMAN growth concerns from management commentary — this confirms the bear case has real fundamental basis, not just sentiment. Counterbalancing this, FDA cleared Penumbra's Thunderbolt thrombectomy platform on June 12, and Boston Scientific's pending Penumbra acquisition gives BSX direct exposure to a newly-approved stroke device that one analyst estimates contributes ~$100M in incremental revenue. SeekingAlpha framed the setup as 'market pricing a broken compounder, we see a reset one' — this is the crux of the debate. Net read: the WATCHMAN/EP issue is the real risk, but at $46.91 with $100M of incremental Penumbra revenue layering in and a still-growing core business, much of the bad news appears priced. The market news (crypto/Trump/Pokemon) is irrelevant noise for BSX.
- Penumbra acquisition closing this year — adds Thunderbolt (FDA cleared June 12, 2026) and broader neurovascular thrombectomy portfolio, est. ~$100M incremental revenue contribution
- Stroke/neurovascular intervention becomes a third major growth pillar alongside cardiology and endoscopy
- WATCHMAN FLX LAAC franchise — currently the source of the guidance cut, but still a multi-billion TAM if growth re-accelerates
- Deep brain stimulation and spinal cord stimulator pipeline within MedSurg neuromodulation
- Sales growth has compounded 16.5%/yr over 3 years and 15.2%/yr over 5 years — base business momentum predates current concerns
- WATCHMAN guidance cut (per Truist June 4) suggests deceleration in a key growth franchise — risk of further negative revisions
- Stock down 50.8% YTD and -52.4% over 1 year — momentum is severely broken; could overshoot to $40 or lower before stabilizing
- Q1'26 operating cash flow dropped to $348M from $1.36B in Q4'25 — needs explanation; could signal working capital stress or one-off
- Penumbra acquisition integration risk and $100M revenue contribution is modest vs $20.6B base
- $11.03B total debt with only $1.45B cash limits flexibility if EBITDA compresses
- Forward P/E of 12.6x looks cheap, but if growth resets to high-single-digits, a 12x multiple may be the new normal not a re-rating opportunity
- Kronos model directional accuracy on BSX is only 23.8% — AI forecast band of $60-86 should not be relied on as a price target
- Inst Own at 92.6% — heavy institutional crowding means continued forced selling possible
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord